Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K.; AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal

Taking stock of the drug industry, from the lab to the medicine chest

March 14, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

JOSEPH PREZIOSO/AFP via Getty Images STAT+ | Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K. The cost-effectiveness agency known as NICE said it wanted more information about Casgevy's effectivenss and durability. By Andrew Joseph STAT+ | AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal The deal for the French firm, worth up to $1 billion, comes as the British pharma giant expands its efforts in rare diseases. By Andrew Joseph STAT+ | Medicare couldn't cover Wegovy for weight loss. But now that it's also a heart drug, the door is open FDA permission for Novo Nordisk to market heart benefits of its obesity drug Wegovy could provide a backdoor way to win Medicare coverage. By Rachel Cohrs Molly Ferguson/STAT STAT+ | Argenx readies another blockbuster opportunity with its antibody drug The company has developed the IgG-lowering antibody Vyvgart to treat patients with chronic inflammatory demyelinating polyneuropathy, or CIDP. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser